免疫检查点LAG-3及其靶向药物研究现状和临床应用进展

doi:10.3969/j.issn.1006-5725.2024.11.024

Abstract

Abstract:

Lymphocyte-activation gene 3 （LAG-3） is an inhibitory immune checkpoint receptor that negatively regulates the function of T cells to prevent over-activation of the immune system from damaging human body. In the existence of tumors and chronic infections， persistent antigenic stimulation induces upregulation of LAG-3 expression in effector T cells， leading to T cell exhaustion and tumor immune escape. Targeting LAG-3 drugs can reactivate the anti-tumor function of T cells by specifically blocking the signaling pathway of LAG-3， and have shown promising efficacy in a variety of solid tumors， hematologic tumors and autoimmune diseases. In this paper， we summarize the current research progress on the structure， ligand and regulatory function of LAG-3， review the current status of clinical trials of LAG-3-targeted drugs， and further discuss the clinical application strategy and development direction of LAG-3-targeted drugs， with a view to providing reference for further in-depth research on LAG-3.

Key words: lymphocyte activation gene 3, immune checkpoint, tumor, therapeutic antibody

CLC Number:

R730.5

Huinan ZHOU,Kewei QIN,Lijun. ZHOU. Current research status and clinical application progress of the immune checkpoint LAG⁃3 and its targeting drugs[J]. The Journal of Practical Medicine, 2024, 40(11): 1607-1612.

References 42

1	MING Q， CELIAS D P， WU C， et al. LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition［J］. Nat Immunol， 2022，23（7）： 1031-1041. doi:10.1038/s41590-022-01238-7 doi: 10.1038/s41590-022-01238-7
2	TRIEBEL F， JITSUKAWA S， BAIXERAS E， et al. LAG-3， a novel lymphocyte activation gene closely related to CD4［J］. J Exp Med， 1990，171（5）： 1393-1405. doi:10.1084/jem.171.5.1393 doi: 10.1084/jem.171.5.1393
3	WORKMAN C J， DUGGER K J， VIGNALI D A. Cutting edge： molecular analysis of the negative regulatory function of lymphocyte activation gene-3［J］. J Immunol， 2002，169（10）： 5392-5395. doi:10.4049/jimmunol.169.10.5392 doi: 10.4049/jimmunol.169.10.5392
4	MAEDA T K， SUGIURA D， OKAZAKI I M， et al. Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation［J］. J Biol Chem， 2019，294（15）： 6017-6026. doi:10.1074/jbc.ra119.007455 doi: 10.1074/jbc.ra119.007455
5	XU F， LIU J， LIU D， et al. LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses［J］. Cancer Res， 2014，74（13）： 3418-3428. doi:10.1158/0008-5472.can-13-2690 doi: 10.1158/0008-5472.can-13-2690
6	KOUO T， HUANG L， PUCSEK A B， et al. Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8⁺ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells［J］. Cancer Immunol Res， 2015，3（4）： 412-423. doi:10.1158/2326-6066.cir-14-0150 doi: 10.1158/2326-6066.cir-14-0150
7	WANG J， SANMAMED M F， DATAR I， et al. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3［J］. Cell， 2019，176（1-2）： 334-347. doi:10.1016/j.cell.2018.11.010 doi: 10.1016/j.cell.2018.11.010
8	贾王强，倪红谚，袁龙. FGL-1作为LAG-3主要的免疫抑制配体在恶性肿瘤中的研究进展［J］. 实用医学杂志， 2021，37（4）： 547-551. doi:10.3969/j.issn.1006-5725.2021.04.026 doi: 10.3969/j.issn.1006-5725.2021.04.026
9	MARUHASHI T， SUGIURA D， OKAZAKI I M， et al. Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity［J］. Immunity， 2022，55（5）： 912-924. doi:10.1016/j.immuni.2022.03.013 doi: 10.1016/j.immuni.2022.03.013
10	GUY C， MITREA D M， CHOU P， et al. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation［J］. Nat Immunol， 2022，23（5）： 757-767. doi:10.1038/s41590-022-01176-4 doi: 10.1038/s41590-022-01176-4
11	MAO X， OU M T， KARUPPAGOUNDER S S， et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3［J］. Science， 2016，353（6307）：aah3374.
12	GREBINOSKI S， ZHANG Q， CILLO A R， et al. Autoreactive CD8（⁺） T cells are restrained by an exhaustion-like program that is maintained by LAG3［J］. Nat Immunol， 2022，23（6）： 868-877. doi:10.1038/s41590-022-01210-5 doi: 10.1038/s41590-022-01210-5
13	KURACHI M. CD8（+） T cell exhaustion［J］. Semin Immunopathol， 2019，41（3）： 327-337. doi:10.1007/s00281-019-00744-5 doi: 10.1007/s00281-019-00744-5
14	DAI E， ZHU Z， WAHED S， et al. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy［J］. Mol Cancer， 2021，20（1）： 171. doi:10.1186/s12943-021-01464-x doi: 10.1186/s12943-021-01464-x
15	SUNG E， KO M， WON J， et al. LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation［J］. Mol Ther， 2022，30（8）： 2800-2816. doi:10.1016/j.ymthe.2022.05.003 doi: 10.1016/j.ymthe.2022.05.003
16	CAMISASCHI C， DE FILIPPO A， BERETTA V， et al. Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions： involvement of LAG-3［J］. J Invest Dermatol， 2014，134（7）： 1893-1902. doi:10.1038/jid.2014.29 doi: 10.1038/jid.2014.29
17	YANG L L， MAO L， WU H， et al. pDC depletion induced by CD317 blockade drives the antitumor immune response in head and neck squamous cell carcinoma［J］. Oral Oncol， 2019，96： 131-139. doi:10.1016/j.oraloncology.2019.07.019 doi: 10.1016/j.oraloncology.2019.07.019
18	LIANG B， WORKMAN C， LEE J， et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II［J］. J Immunol， 2008，180（9）： 5916-5926. doi:10.4049/jimmunol.180.9.5916 doi: 10.4049/jimmunol.180.9.5916
19	GHOSH S， SHARMA G， TRAVERS J， et al. TSR-033， a Novel Therapeutic Antibody Targeting LAG-3， Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo［J］. Mol Cancer Ther， 2019，18（3）： 632-641. doi:10.1158/1535-7163.mct-18-0836 doi: 10.1158/1535-7163.mct-18-0836
20	邓俊，王均，高嫦娥，等. 免疫检查点抑制剂毒性预测生物标志物的研究进展［J］. 实用医学杂志， 2023，39（20）： 2561-2565. doi:10.3969/j.issn.1006-5725.2023.20.001 doi: 10.3969/j.issn.1006-5725.2023.20.001
21	张陈，刘平，于晓杰，等. 新型全人源LAG3单克隆抗体的体外抗肿瘤作用及其机制初探［J］. 中国肿瘤生物治疗杂志， 2022，29（5）： 419-425.
22	PREVITE D M， MARTINS C P， O'CONNOR E C， et al. Lymphocyte Activation Gene-3 Maintains Mitochondrial and Metabolic Quiescence in Naive CD4（+） T Cells［J］. Cell Rep， 2019，27（1）： 129-141. doi:10.1016/j.celrep.2019.03.004 doi: 10.1016/j.celrep.2019.03.004
23	HUANG R Y， FRANCOIS A， MCGRAY A R， et al. Compensatory upregulation of PD-1， LAG-3， and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer［J］. Oncoimmunology， 2017，6（1）： e1249561. doi:10.1080/2162402x.2016.1249561 doi: 10.1080/2162402x.2016.1249561
24	HUANG R Y， EPPOLITO C， LELE S， et al. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8⁺ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model［J］. Oncotarget， 2015，6（29）： 27359-27377. doi:10.18632/oncotarget.4751 doi: 10.18632/oncotarget.4751
25	TAWBI H A， SCHADENDORF D， LIPSON E J， et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma［J］. N Engl J Med， 2022，386（1）： 24-34. doi:10.1056/nejmoa2109970 doi: 10.1056/nejmoa2109970
26	AMARIA R N， POSTOW M， BURTON E M， et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma［J］. Nature， 2022，611（7934）： 155-160. doi:10.1038/s41586-022-05368-8 doi: 10.1038/s41586-022-05368-8
27	WANG J B， QIU Q Z， ZHENG Q L， et al. Tumor Immunophenotyping-Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer［J］. Adv Sci （Weinh）， 2023， 10（15）：e2207417. doi:10.1002/advs.202207417 doi: 10.1002/advs.202207417
28	THUDIUM K， SELBY M， ZORN J A， et al. Preclinical Characterization of Relatlimab， a Human LAG-3-Blocking Antibody， Alone or in Combination with Nivolumab［J］. Cancer Immunol Res， 2022，10（10）： 1175-1189. doi:10.1158/2326-6066.cir-22-0057 doi: 10.1158/2326-6066.cir-22-0057
29	SANGRO B， NUMATA K， HUANG Y， et al. Relatlimab plus nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors， a phase 2， randomized， open-label study： RELATIVITY-073［J］. Ann Oncol， 2021，32： S117. doi:10.1016/j.annonc.2021.05.116 doi: 10.1016/j.annonc.2021.05.116
30	HAMID O， WANG D， KIM T M， et al. Clinical activity of fianlimab （REGN3767）， a human anti-LAG-3 monoclonal antibody， combined with cemiplimab （anti-PD-1） in patients （pts） with advanced melanoma.［J］. J Clin Oncol， 2021，39（）：9515. doi:10.1200/jco.2021.39.15_suppl.9515 doi: 10.1200/jco.2021.39.15_suppl.9515
31	HAMID O， LEWIS K D， WEISE A， et al. 400P Phase I study of fianlimab， a human lymphocyte activation gene-3 （LAG-3） monoclonal antibody， in combination with cemiplimab in advanced melanoma （mel）［J］. Ann Oncol， 2022，33： S1598. doi:10.1016/j.annonc.2022.10.431 doi: 10.1016/j.annonc.2022.10.431
32	YU X， HUANG X， CHEN X， et al. Characterization of a novel anti-human lymphocyte activation gene 3 （LAG-3） antibody for cancer immunotherapy［J］. MAbs， 2019，11（6）： 1139-1148. doi:10.1080/19420862.2019.1629239 doi: 10.1080/19420862.2019.1629239
33	SHI Y， LUO S， ZHOU H， et al. Phase I study of LBL-007， a novel anti-human lymphocyte activation gene 3 （LAG-3） antibody in patients with advanced solid tumors［J］. J Clin Oncol， 2021，39（）： 2523. doi:10.1200/jco.2021.39.15_suppl.2523 doi: 10.1200/jco.2021.39.15_suppl.2523
34	BAI X， LI M， PU X X， et al. Anti-LAG-3 antibody LBL-007 in combination with toripalimab in patients with unresectable or metastatic melanoma： A phase.， open-label， multicenter， dose escalation/expansion study［J］. J Clin Oncol， 2022，40（）：9538. doi:10.1200/jco.2022.40.16_suppl.9538 doi: 10.1200/jco.2022.40.16_suppl.9538
35	RADER C. Bispecific antibodies in cancer immunotherapy［J］. Curr Opin Biotechnol， 2020，65： 9-16. doi:10.1016/j.copbio.2019.11.020 doi: 10.1016/j.copbio.2019.11.020
36	WANG J， ASCH A S， HAMAD N， et al. A Phase 1， Open-Label Study of MGD013， a Bispecific DART^® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma［J］. Blood， 2020，136： 21-22. doi:10.1182/blood-2020-139868 doi: 10.1182/blood-2020-139868
37	OH D Y， BANG Y J. HER2-targeted therapies-a role beyond breast cancer［J］. Nat Rev Clin Oncol， 2020，17（1）： 33-48. doi:10.1038/s41571-019-0268-3 doi: 10.1038/s41571-019-0268-3
38	CATENACCI D， ROSALES M K， CHUNG H， et al. P-342 Margetuximab combined with anti-PD-1 （MGA012） or anti-PD-1/LAG-3 （MGD013） +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer［J］. Ann Oncol， 2020， 31（3）：S201. doi:10.1016/j.annonc.2020.04.424 doi: 10.1016/j.annonc.2020.04.424
39	KRAMAN M， FAROUDI M， ALLEN N L， et al. FS118， a Bispecific Antibody Targeting LAG-3 and PD-L1， Enhances T-Cell Activation Resulting in Potent Antitumor Activity［J］. Clin Cancer Res， 2020，26（13）： 3333-3344. doi:10.1158/1078-0432.ccr-19-3548 doi: 10.1158/1078-0432.ccr-19-3548
40	YAP T A， LORUSSO P M， WONG D J， et al. A Phase 1 First-in-Human Study of FS118， a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance［J］. Clin Cancer Res， 2023，29（5）： 888-898. doi:10.1158/1078-0432.ccr-22-1449 doi: 10.1158/1078-0432.ccr-22-1449
41	EDWARDS C J， SETTE A， COX C， et al. The multi-specific V（H）-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity［J］. Br J Cancer， 2022，126（8）： 1168-1177. doi:10.1038/s41416-021-01684-4 doi: 10.1038/s41416-021-01684-4
42	LEGAT A， MABY-EL H H， BAUMGAERTNER P， et al. Vaccination with LAG-3Ig （IMP321） and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients-Report of a Phase I/IIa Clinical Trial［J］. Clin Cancer Res， 2016，22（6）： 1330-1340. doi:10.1158/1078-0432.ccr-15-1212 doi: 10.1158/1078-0432.ccr-15-1212

[1]	Wei HE,Liping LIU,Jingwei ZHUO,Xiaodong ZHANG,Tong YANG,Jubin. FENG. CCR5 blockade reduces tumor growth by inducing apoptosis and impairing immunosuppression of tumor microenvironment [J]. The Journal of Practical Medicine, 2024, 40(9): 1204-1210.
[2]	Yuxuan DING,Lining GUO,Jiayi SHEN,Lijun. WANG. Safety and efficacy of radiotherapy and PD⁃1/PD⁃L1 inhibitor + TKI for MSS/pMMR colorectal cancer with liver metastases [J]. The Journal of Practical Medicine, 2024, 40(9): 1293-1297.
[3]	Xiaona MENG,Xu SUN,Huaimin LIU. Advances in the study of immune checkpoint inhibitors⁃related colitis [J]. The Journal of Practical Medicine, 2024, 40(9): 1314-1319.
[4]	Xiya MA,Hu JI,Zehua ZHU,Bo PAN,Qiang XIE,Xiaobo. YAO. The predictive value of ¹⁸F⁃FDG PET/CT metabolic heterogeneity parameters combined with clinical features for the prognosis of esophageal squamous cell carcinoma before definitive radiochemotherapy [J]. The Journal of Practical Medicine, 2024, 40(7): 966-971.
[5]	Ting XU,Wei HUANG,Li YANG,Hao. YU. Tumor endothelial markers1 mediate endothelial cell angiogenesis and heart failure myocardial remodeling via MAPKs pathway [J]. The Journal of Practical Medicine, 2024, 40(6): 780-786.
[6]	Yaqi WANG,Wanfu LI,Maimaijiang AYIGUZALI,Kramer ANIWAR,Jiarong FAN,Peng LIANG,Samusiddin. NAFISA. Study on the effect of miR⁃20a⁃5p on human nephroblastoma cell WiT49 transplanted in nude mice [J]. The Journal of Practical Medicine, 2024, 40(4): 490-495.
[7]	Yigang TAN,Haobin KUANG,Hongmei FU,Chunyan LI,Xiaobing ZHAO,Lijing XUE. Analysis of clinical characteristics of 33 cases of tuberculosis complicated by tumor necrosis factor⁃α inhibitor in autoimmune diseases [J]. The Journal of Practical Medicine, 2024, 40(3): 378-383.
[8]	Jiang SHAO,Lin LI,Yansong GUO,Chengyuan SUN,Xichao WEN,Kebin ZHENG,Yanfang SHI. Research progress of CD73/NT5E in glioblastoma [J]. The Journal of Practical Medicine, 2024, 40(3): 428-431.
[9]	Kunyuan HUANG,Kehua JIANG,Qing WANG. Research progress of S100A9 in renal diseases [J]. The Journal of Practical Medicine, 2024, 40(22): 3251-3255.
[10]	Yuqiao ZHANG,Weijian MEI. Landmark Achievements in Treating Solid Tumors with Immune Checkpoint Inhibitors [J]. The Journal of Practical Medicine, 2024, 40(2): 272-277.
[11]	Xing LI,Youcai WANG,Yongchao XU,Ligong TANG,Fangyuan. CHENG. Application of prophylactic ileostomy through right lower abdominal specimen extraction incision in laparoscopic rectal low anterior resection [J]. The Journal of Practical Medicine, 2024, 40(19): 2720-2725.
[12]	Rui WANG,Duo LI,Zhao PENG,Lijun CUI,Xiang ZHANG,Kaili FAN,Wenyan. WU. Effect of endoscopic tumor resection by submucosal tunnel on recurrence in patients with submucosal tumors around cardia [J]. The Journal of Practical Medicine, 2024, 40(18): 2555-2560.
[13]	Zhaochen SUN,Junyan JIANG,Yitian. CHEN. Advancements in CAR⁃T cell research for the treatment of colorectal cancer [J]. The Journal of Practical Medicine, 2024, 40(18): 2640-2646.
[14]	Kengjun LUO,Wenbo ZHANG,Pengcheng. JIANG. Research advance on long non⁃coding RNA regulating myeloid⁃derived suppressor cells in tumors [J]. The Journal of Practical Medicine, 2024, 40(18): 2647-2653.
[15]	Qingwei ZHANG,Rutie. YIN. Hotspots and advances on diagnosis and treatment for cervical cancer [J]. The Journal of Practical Medicine, 2024, 40(17): 2357-2362.

Current research status and clinical application progress of the immune checkpoint LAG⁃3 and its targeting drugs

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 42

Related Articles 15

Recommended Articles

Metrics

Comments